Pharmaceutical giant Roche announced Thursday that its experimental weight loss medication achieved remarkable results in a recent clinical trial, with participants shedding nearly 11% of their body weight.
The drug, known as petrelintide, was tested on 493 patients over a 42-week period. Results showed participants experienced weight reduction of up to 10.7%, significantly surpassing the minimal 1.7% weight loss observed in those receiving placebo treatments.
The Swiss pharmaceutical company obtained rights to develop petrelintide through a partnership agreement with Zealand Pharma, a Danish biotechnology firm, established in the previous year. This licensing arrangement provides Roche with joint development authority over the amylin-based weight management treatment.
